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Membrane-bindingEnfuvirtide (T20), the ﬁrst FDA-approved peptide HIV fusion/entry inhibitor derived from the HIV-1 gp41
C-terminal heptad-repeat (CHR) domain, is believed to share a target with C34, another well-characterized
CHR-peptide, by interacting with the gp41 N-terminal heptad-repeat (NHR) to form six-helix bundle core.
However, our previous studies showed that T20 mainly interacts with the N-terminal region of the NHR
(N-NHR) and lipid membranes, while C34 mainly binds to the NHR C-terminal pocket region. But so far, no
one has shown that C34 can induce drug-resistance mutation in the gp41 pocket region. In this study, we
constructed pseudoviruses in which the Ala at the position of 67 in the gp41 pocket region was substituted
with Asp, Gly or Ser, respectively, and found that these mutations rendered the viruses highly resistant to
C34, but sensitive to T20. The NHR-peptide N36 with mutations of A67 exhibited reduced anti-HIV-1 activity
and decreased α-helicity. The stability of six-helix bundle formed by C34 and N36 with A67 mutations was
signiﬁcantly lower than that formed by C34 and N36 with wild-type sequence. The combination of C34
and T20 resulted in potent synergistic anti-HIV-1 effect against the viruses with mutations in either N- or
C-terminal region in NHR. These results suggest that C34 with a pocket-binding domain and T20 containing
the N-NHR- and membrane-binding domains inhibit HIV-1 fusion by interacting with different target sites
and the combinatorial use of C34 and T20 is expected to be effective against HIV-1 variants resistant to
HIV fusion inhibitors.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The fusion event of the human immunodeﬁciency virus type 1
(HIV-1) with its target cells is mediated by two noncovalently linked
glycoprotein subunits, gp120 and gp41 [1]. Initially, gp120 binds to
the cellular receptor CD4 and a coreceptor CCR5 or CXCR4, triggering
a series of conformation rearrangements in gp41. Then, gp41 fusionR, C-terminal heptad repeat;
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l rights reserved.peptide (FP) exposes and inserts itself into the target cell membrane
[2–4]. Conformational changes subsequently occur, bringing the gp41
N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR)
domains (Fig. 1A) together to form a thermostable six-helix bundle
(6-HB) core structure [5–7], which then brings the host and viral
membranes into close proximity for membrane fusion [8,9].
The peptides derived from the CHR domain, such as SJ-2176
(residues 119–148) [10,11], DP-178 (also known as T20; residues
127–162) [12,13], and C34 (residues 117–150) [6,14], exhibit po-
tent HIV-1 fusion inhibitory activity. Some of the peptides derived
from the NHR domain, such as DP-107 (also known as T21; residues
42–79) [15] and N36 (residues 35–70) [6,14], also show anti-HIV-1
activity. C34 is the best-characterized CHR-peptide because the crys-
tal structure of the complex of C34 and N36 was solved [6]. It was
shown that C34 binds in an antiparallel manner into hydrophobic
grooves on the outer surface of the internal trimeric NHR coiled-coil
formed by N36. A deep hydrophobic pocket is formed by residues
54–70 of the C-terminal region of NHR domain in each of the grooves
of NHR-trimer. The residues in this pocket are believed to be crucial
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Fig. 1. Functional domains and hydrophobic pocket of HIV-1 gp41. (A) Schematic representation of gp41 functional domains and corresponding peptide sequences. The residue
number corresponds to HIV-1 HXB2 gp160 sequence. FP, fusion peptide; TM, transmembrane domain; CP, cytoplasmic domain; PBD, pocket-binding domain; PFD,
pocket-forming domain; MPD, membrane-binding domain. (B) Interaction between the NHR and CHR. The letters “a–g” indicate the positions of the corresponding residues in
the helical wheel of the gp41 NHR domain. Residue A67 is located at the f site in the helical wheel of the gp41 NHR domain, which does not involve direct interaction with the
key residues in NHR for forming N-trimer or those in CHR for forming 6-HB. The sequences of N36, T20 and C34 are also shown. (C) Model of 6-HB formed by the N- and
C-helices. The 6-HB is formed through the interaction of residues located at the e and g positions (in red) in the N-helices and those at a and d positions (in blue) in the
C-helices. Residue A67 located at the f site is also shown.
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in the pocket-binding domain (PBD; residues 117–124) in C34 pep-
tide and other PBD-containing CHR-peptides are critical for the for-
mation of 6-HB with the viral gp41 NHR domain and for their anti-
HIV-1 activity [18–22].
T20 (generic name: enfuvirtide; brand name: Fuzeon) is the ﬁrst
U.S. FDA-approved HIV fusion/entry inhibitor for clinical use [23,24].
Since both T20 and C34 peptides have an overlapping sequence
in CHR domain,viruses with mutations in the GIV motif (residues
36–44) in the N-terminal region of the NHR domain are rendered
highly resistant to T20 [25–30] and partially resistant to C34 [31]. It
has been widely believed that T20 and C34 share a common target,
i.e., inhibition of HIV fusion with the target cell membrane by binding
to the viral NHR domain to block the fusion core formation. However,
our previous studies have suggested that T20 and C34 may have dif-
ferent target sites because they contain different functional domains
[21,22]. C34 mainly interacts through its PBD with essentially the
pocket region in the C-terminal region of NHR domain, to form a stable
6-HB and block viral fusion core formation. However, T20, which lacks
the PBD, mainly binds to the N-terminal region of the NHR domain
(N-NHR), where the GIV motif is located, and interacts with the cell
membrane via its membrane-binding domain (MBD) or tryptophan-
rich domain (residues 155–162) [20–22,32,33]. Shai and colleagues
have demonstrated that T20's MBD (WNWF) is critical for its antiviral
activity since replacement of WNWF in T20 with ANAA results in
loss of its anti-HIV-1 activity, while addition of an ocytl group to theC-terminus of the T20-ANAA mutant rescues this inactive mutant to
an anti-HIV-1 potency similar to that of the wild-type T20 [32]. How-
ever, our hypothesis is not veriﬁed by mutation studies since it has
not, thus far, been shown that the CHR-peptides containing the PBD
could induce drug-resistant mutations in the gp41 pocket region.
In this study, we aimed to circumvent this obstacle by arbitrarily
introducingmutations into the pocket region in gp41 of pseudoviruses
and comparing the susceptibility of themutant viruseswith that of the
wild-type virus to C34 and T20. We found that the substitutions of Ala
at the position of 67 in the gp41 NHR C-terminal pocket region with
Asp, Gly or Ser (A67D/G/S) rendered the viruses resistant to C34, but
sensitive to T20. We also demonstrated that the combination of C34
and T20 exhibited strong synergistic antiviral effect against HIV-1
strain IIIB and those strains resistant to T20 and/or C34. These ﬁndings
conﬁrm that C34 and T20 inhibited viral fusion by interactingwith dif-
ferent target sites. The combinatorial use of T20 with C34 and other
CHR-peptides containing PBD resulted in synergistic anti-HIV-1 activ-
ity, thus suggesting a potential regimen for treating patients infected
by HIV-1 isolates with resistance to HIV entry inhibitors.
2. Materials and methods
2.1. Materials
TZM-bl and MT-2 cell lines, HIV-1 strain IIIB, NL4-3 and its mu-
tants, and the plasmid encoding HIV-1 HXB2-Env (pHXB2-Env) were
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Peptides N36 and its mutants (N36-A67D, N36-A67G and N36-A67S),
C34 and T20 were synthesized by a standard solid-phase FMOCmeth-
od using an Applied Biosystems model 433A peptide synthesizer. The
N- and C-termini of these peptides were acetylated and amidated, re-
spectively. The peptides were puriﬁed to homogeneity (>95% purity)
by high-performance liquid chromatography and veriﬁed by laser de-
sorption mass spectrometry (PerSeptive Biosystems, Framingham,
MA). The concentration of these peptides was decided by UV absor-
bance at 280 nm, according to the theoretically calculated molar ex-
tinction coefﬁcients (ε) (280 nm) of 5500 and 1490 mol/l−1 cm−1
based on the number of tryptophan (Trp) residues and tyrosine
(Tyr) residues (all peptides tested contain Trp and/or Tyr), respective-
ly [34].
2.2. Generation of HIV-1 pseudoviruses
Pseudovirus with wild-type, or mutant, Env protein was pro-
duced and evaluated for infectivity as previously described [35,36].
Brieﬂy, A67D, A67G and A67S mutations were introduced into the
pHXB2-Env using the QuikChange® Site-Directed Mutagenesis Kit
(Stratagene). The plasmid encoding wild-type or mutant HXB2-Env
and another plasmid encoding Env-defective, luciferase-expressing
HIV-1 genome (pNL4-3.Luc.R-E-) were co-transfected into HEK293T
cells by using FuGENE 6 reagents (Roche Applied Science). The su-
pernatants were collected at 48 h post-transfection. The superna-
tants were centrifuged at 1000 ×g for 10 min, ﬁltrated through a
0.45-μm ﬁlter, and then concentrated by centrifuging at 26,000 ×g
for 2 h. The concentrations of these pseudovirion stocks were deter-
mined by enzyme-linked immunosorbent assay (ELISA) for p24 anti-
gen (Coulter) and stored at 80 °C.
2.3. Single-cycle infection and drug inhibition assays
About 104 TZM-bl cells/well were plated in 96-well dishes in
Dulbecco's Modiﬁed Eagle's Medium (DMEM). The dosage of
pseudovirion stocks was ﬁxed at approximately 250 ng of p24 per
ml for single-cycle infection and 200 ng of p24 per ml for viral inhibi-
tion assay. The pseudovirus infected the cells in the presence or ab-
sence of peptide in a total volume of 100 μl with 10 μg of Polybrene
(Sigma) per ml. After 16 h of incubation, the medium was changed
with 100 μl of fresh DMEM, and the cultures were left to grow for an
additional 48 h at 37 °C. Then the cells were harvested, washed with
PBS and lysed using the lysis reagent from a luciferase kit (Promega,
Madison, WI). The cell lysates were transferred to 96-well Costar
ﬂat-bottom luminometer plates (Corning Costar, Corning, NY), fol-
lowed by addition of luciferase substrate (Promega), and tested im-
mediately for the luciferase activity (relative light units: RLU) in an
Ultra 384 luminometer (Tecan US) [37]. The relative infection activity
was calculated using the following formula: [(E−N)/(P−N)]×100%,
where E, P and N represent the luciferase activity (RLU) of the exper-
imental group (cells+peptide+virus), the positive control group
(cells+PBS+virus), and the negative control group (cells+PBS+
PBS), respectively.
2.4. CD spectroscopy
The secondary structure of N peptides and the mutants (or their
complexes with C peptide) was determined by CD spectroscopy. All
the peptides were dissolved in PBS to 10 μM (pH 7.2). An N-peptide
(N36 or its mutants) was incubated with the C-peptide (C34) at 37 °C
for 30 min before measurement. The separated N- and C-peptides
were also measured. Circular dichroism (CD) spectra of these peptides
and peptide mixtures were acquired on a Jasco spectropolarimeter
Model J-715 (Jacobin, Japan) at room temperature using a 5.0 nmband-
width, 0.1 nm resolution, 0.1 cm path length, 4.0 sec response time,and a 50 nm/min scanning speed. The spectra were corrected by
subtraction of a blank corresponding to the solvent. The α-helicity
was determined from the CD signal by dividing the mean residue ellip-
ticity at 222 nm according to a previously used value of 33,000 degrees
dmol−1as 100% helix formation [38]. Thermal denaturation of the
proteinwas inspected at 222 nmbymonitoring a temperature gradient
from 5 °C to 80 °C with a 2-degree interval, an equilibration time of
1.5 min, and an averaging time of 60s.
2.5. Native polyacrylamide gel electrophoresis (N-PAGE)
N-PAGE was used to detect the effect of the mutations on for-
mation of 6-HB between the N-peptide and C-peptide as described
previously [39]. Brieﬂy, the mixture of an N-peptide (N36 or its mu-
tants) and C-peptide C34 with different concentrations (60 μM, N36;
60 μM, C34) was incubated at 37 °C for 30 min and loaded onto
Tris-glycine gels (18%; Invitrogen). Then gel electrophoresis was car-
ried out at 125 V constant voltages at room temperature for 2 h. The
gels were stained with Coomassie Blue and imaged with a FluorChem
8800 imaging system (Alpha Innotech Corp., San Leandro, CA).
2.6. Measurement of HIV-1IIIB infectivity
The inhibitory activity of peptide N36 or its mutants on infection
by a laboratory-adapted HIV-1 strain (IIIB) was tested as previously
described [40]. Brieﬂy, 1×104/ml MT-2 cells were infected with
HIV-1 isolates at 100 TCID50 (50% tissue culture infective dose) in
200 μl RPMI 1640 medium in the presence or absence of the test pep-
tides overnight. Then the culture supernatants were taken out, and
fresh media were added. On the fourth day post-infection, 100 μl of
culture supernatants were collected from each well, mixed with
equal volumes of 5% Triton X-100, and analyzed for p24 antigen by
ELISA as previously described [41].
2.7. Combination study
The assays for evaluating HIV-1 Env-mediated cell-cell infection
and HIV-1 infection were used to test the synergistic antiviral effect
of the T20/C34 combination as previously described [42]. T20 and
C34 were measured individually, or in combination, at a ﬁxed molar
ratio for the greatest synergism over a range of serial dilutions. The re-
sults were analyzed as previously described [43,44]. The analysis was
executed progressively by calculating IC50 (or IC75, IC90, and IC95)
values based on the inhibition curves of single drug or two drugs test-
ed in combination. Then, the combination index (CI) was determined
by calculating the median effect equation with the CalcuSyn program
(kindly provided by Dr. T. C. Chou at the Memorial Sloan-Kettering
Cancer Center) to assess the synergistic effect of combinations. A CI
of b1 indicates synergism (CI values are interpreted as follows: b0.1,
very strong synergism; 0.1 to 0.3, strong synergism; 0.3 to 0.7, syner-
gism; 0.7 to 0.85, moderate synergism; and 0.85 to 0.90, slight syner-
gism). A CI of 1, or close to 1, indicates additive effects, and a CI of >1
indicates antagonism [43]. Dose reduction was obtained by dividing
the IC50 value of a peptide tested alone by that of the same peptide
tested in combination with other peptides.
3. Results
3.1. Generation of infectious pseudoviruses expressing HIV-1 Env with
mutations of residue A67 in the pocket-forming region of the HIV-1 gp41
NHR domain
To generate infectious virions with mutations in the gp41 pocket
region, we must avoid changing the residues at the a, d, e, and g sites
in the helical wheel of the NHR coiled-coil domain since these residues
are responsible formediating the association among the NHR domains
Table 1
The resistance proﬁle of NL4-3 variants with mutations in the pocket-forming region of
the HIV-1 gp41 NHR domain to the HIV-1 fusion inhibitors T20 and C34.
Virus T20 C34
IC50 Resistance IC50 Resistance
(nM) (n-fold) (nM) (n-fold)
WT 17±0.01 1.0 10±0.01 1.0
V38E/N42S 1790±100.2 105.3 54.13±4.33 5.4
A67D 157±8.5 9.2 1025±6.33 102.5
A67G 21±0.11 1.2 606±20.1 60.6
A67S 58±0.32 3.4 2435±12.7 243.5
IC50 values are presented in nM. Results are derived from experiments performed in
duplicate and are representative of at least three independent experiments.
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CHR domains to form 6-HB core. These residues are highly conserved,
and mutations of these residues may result in noninfectious virions
[18,45,46]. In this study, we selected residue A67 for mutations since
its locus is the f site in the helical wheel of the NHR domains (Fig. 1A
and C). Since it is not located on the hydrophobic interface for interac-
tion among NHRs or interaction with CHR, mutation of this residue
would not signiﬁcantly affect viral infectivity. We constructed three
pseudoviruses with the substitutions of A67 in the gp41 pocket region
with Asp, a negatively charged residue (A67D), or Gly, a residue of
smaller size (A67G), and Ser, a residue with polarity (A67S). These
point mutations were conﬁrmed by sequencing the entire Env gene.
Their infectivity was determined by a luciferase assay. As shown in
Fig. 2, the infectivity of mutant virus A67G had no signiﬁcant decrease,
while the A67D and A67S mutants possessed essential infectivity of
about 45% of the infectivity exhibited by theWT virus. This result sug-
gests that mutations of A67 do not completely disrupt viral infectivity
and that pseudoviruses with these mutations can be used to evaluate
viral susceptibility to antiviral agents.1 10 100 1000
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3.2. Pseudoviruses with mutations of A67 in the gp41 pocket region were
resistant to C34, but relatively sensitive to T20
We investigated the possible susceptibility of the mutant viruses
to the peptide HIV fusion inhibitors with or without pocket-binding
sequence. As shown in Table 1 and Fig. 3, all the variants with substi-
tutions at position 67 in the pocket region showed high resistance to
C34 (ranging from 61- to 244-fold). However, while the viruses with
A67G mutation showed no resistance to T20, those with A67S and
A67D exhibited a low level of resistance to T20. These results indicate
that the mutation in the C-terminal pocket region of the gp41 NHR
domain results in increased resistance to C34 which contains the
pocket-binding sequence, while the viruses with these mutations re-
tain their sensitivity to T20, which lacks the pocket-binding sequence.
We also compared the sensitivity of the virus with V38E/N42S muta-
tions in the GIV motif in the N-terminal region of the gp41 NHR do-
main to T20 and C34. This virus was very resistant to T20 (about
105-fold) and moderately resistant to C34 (about 5-fold), results
which are consistent with our previous reports [37].HIV-1 pseudovirus
WT A67D A67G A67S
Lu
ci
fe
ra
se
 a
ct
iv
ity
 
(R
LU
)
0
10000
20000
30000
40000
50000
60000
70000
80000
Fig. 2. Infectivity of HIV-1 pseudoviruses bearing wild-type or mutant HXB2 Env.
Single-cycle infection of the different pseudoviruses bearing A67 mutations on TZM-bl
cells was measured by a luciferase-based assay using luciferase kit from Promega. The lu-
ciferase activity (relative light units: RLU) was detected using an Ultra 384 luminometer
from Tecan US. WT, wild type.3.3. Mutations of A67 in the gp41 pocket region resulted in decreased
α-helicity and stability of 6-HB formed by N36 and C34
To understand the resistancemechanism of A67mutants, we stud-
ied the biophysical properties of NHR-peptide N36 and its mutants
using CD spectroscopy. As shown in Fig. 4 and Table 2, the isolated
N36 peptide displayed low α-helicity (29.9%), which is consistentConcentration of C34 (nM)
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Fig. 3. Inhibitory activity of HIV-1 fusion inhibitors on infection of pseudoviruses ex-
pressing wild-type and mutated gp41. Single-cycle infection experiments using TZM-bl
cells were performed to test the inhibitory activity of T20 (A) and C34 (B) on infection of
the pseudoviruses with or without mutation. The relative infection activity of each
pseudovirus in the presence of an inhibitory peptide was calculated based on their lucifer-
ase activity (RLU) in comparisonwith that of the virus in the absence of the inhibitory pep-
tide. Error barswere standard deviation (SD) from at least three independent experiments.
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Fig. 4. CD spectra of separated N-peptides or the mixture of N-peptides and C-peptide.
CD spectroscopy was used to determine the secondary structure of N peptides N36 and
its mutants (A) and 6-HB formed by the mixture of C34 with N36 or its mutants (B).
Both the N- and C-peptides were dissolved in PBS (pH 7.2) to 10 μM. The α-helicity
was calculated from the CD signal as described in the Materials and Methods.
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A67D, N36-A67G, and N36-A67S displayed reduced α-helicity in the
range of 12.6% to 22.0%. Then, we analyzed the secondary structures
of the 6-HB formed by the interaction of C34withN36 and itsmutants.
The mixture of C34 and N36 with WT sequence at equimolar concen-
tration formed a typical helical conformation with high α-helicity, as
shown by the obvious saddle-shaped negative peak in the wavelength
of 200–230 nm in the CD spectrum. All A67 mutants could still inter-
act with C34 to form 6-HBs, but their α-helical contents were sig-
niﬁcantly reduced. To determine the stability of the variant 6-HBs
formed by N- and C-peptides, we performed thermal denaturation
analysis by monitoring the CD signal at 222 nm over a temperature
range. The melting curves of each protein and their thermal unfoldingTable 2
The α-helical content of N36 and its mutants, as well as their mixtures with C34.
N-peptide [θ] 222 nm (×103) % Helicity Tm (0C)
N36 −9.9 29.9 NA
N36 A67D −7.2 22.0 NA
N36 A67G −7.1 21.0 NA
N36 A67S −4.1 12.6 NA
N36+C34 −31.6 96 66
N36 A67D+C34 −24.8 75 53
N36 A67G+C34 −28.0 87 62
N36 A67S+C34 −24.6 74 58
The thermal stability of 6-HB formed by the mixture of N-peptide with C34 at 10 μM in
PBS (pH 7.0) for CD measurement.transition (Tm) values were shown in Table 2. The Tm of the 6-HB
formed by C34 and the wild-type N36 was 66 °C, while the Tm values
of those formed by C34 and the N36 mutants decreased to 53–62 °C.
These results suggested that mutations of A67 in the gp41 pocket re-
gion can impair the ability of NHR domains to form α-helical coiled-
coil structure, which is important for viral fusion.
3.4. Substitutions of A67 might change the conformation of 6-HBs
To test if the mutations affect the conﬁguration of the variant 6-HB
formed by N- and C-peptides, we used N-PAGE to visualize the 6-HB
formed by N36/C34 [22,39]. As shown in Fig. 5, the peptide N36
(lane 1) and its mutants exhibited no band because they carries net
positive charges and may migrate off the gel [22]. C34 exhibited a
band shown in the lower portion of the gel, which is consistent
with a previous study [22]. When N36 and its mutants were mixed
with C34 peptide, the bands corresponding to the variant 6-HBs
appeared. However, all bands of 6-HB formed by the C34 and N36
mutants shifted downward in the gel. Since the locations of these
6-HBs in the gel are determined by several factors, such as net charge,
shape, and molecular size, this result suggests that the conﬁguration
of the 6-HBs formed by C34 and N36 with A67mutations may change.
3.5. Mutations of A67 in N36 peptide resulted in signiﬁcant reduction of
peptide-mediated anti-HIV-1 activity
The NHR peptide N36 possesses anti-HIV-1 activity since it can
interact with the viral gp41 CHR domain and block viral gp41 6-HB
core formation. To determine the potential effect of A67 mutations
on the functionality of N36, the inhibitory activities of N36 and its
mutants upon infection by HIV-1 IIIB were measured. As shown in
Fig. 6, wild-type N36 potently inhibited viral infectivity with IC50 at
about 1 μM, while the N36 mutants exhibited signiﬁcantly reduced
anti-HIV-1 activity with IC50 values ranging from 2 to 14 μM. These
data were consistent with the α-helicity and Tm values of the mutant
peptides as determined by CD spectroscopy (Table 2).
3.6. Combining T20 with C34 produced exceptionally potent synergism
against HIV-1-mediated cell-cell fusion and infection by HIV-1IIIB and
resistant strains
Since T20 and C34 may adapt different mechanisms to inhibit
HIV-1 infection, we investigated the potential cooperative effects of
T20 with C34 on HIV-1-mediated cell-cell fusion (Table 3). Strikingly,C34
6-HB
Fig. 5. Determination of the 6-HB formation between wild-type/mutant N36 and C34
by N-PAGE. The bands of the individual C-peptides and 6-HBs formed by the N- and
C-peptides in the gel were revealed by Coomassie Blue staining. Final concentration
of each peptide is 60 μM. N-peptide N36 and its mutants exhibited no band because
they carried net positive charges and may migrate off the gel.
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Fig. 7. Synergistic effect of combinations of T20 with C34 on inhibition of pseudoviruses
with mutation V38E/N42S (A) or A67G mutation (B). The potential synergistic antiviral
effect of the T20/C34 combination on inhibition of HIV-1 Env-mediated cell-cell infec-
tion and HIV-1 infection were tested as previously described [42]. The IC50 (nM) values
of T20 alone, C34 alone, T20 in the mixture or C34 in the mixture for inhibiting infection
by V38E/N42S mutant or A67G mutant, respectively, were shown in the ﬁgure. Each
sample was tested in triplicate and the data were presented in mean±SD. The experi-
ment was repeated twice, and a representative set of data is shown.
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a 400- to 600-fold dose reduction. We then tested the potential syn-
ergistic effect against infection by laboratory-adapted HIV-1IIIB strain.
We obtained a similar result, i.e., combining T20 and C34 resulted in a
potent synergism with a CI of b0.01 (Table 3). We further determined
whether the combination of T20 and C34 is also synergistic against
HIV-1 strains resistant to T20 and/or C34. As shown in Fig. 7, the
T20/C34 combination exhibited potent synergistic antiviral effect
against both T20-resistant strain V38E/N42S and C34-resistant strain
A67S, suggesting that T20 and C34 may be used in combination for
treating patients infected by HIV-1 strains resistant to HIV fusion in-
hibitors targeting gp41.
4. Discussion
T20, which is derived from the C-terminal sequence of the HIV-1
gp41 CHR domain, is a potent HIV-1 fusion inhibitor [12,13,24,47,48].
In 2003, it was licensed by the U.S. FDA as the ﬁrst member of a new
class of anti-HIV drugs known as HIV fusion/entry inhibitors for the
treatment of HIV-infected patients who fail to respond to the current
antiretroviral therapeutics [24]. CD analysis showed that T20 could
disrupt the stable α-helical structure of the NHR-peptide DP-107 and
that the inhibitory activity of T20 correlated with its ability to interact
with the NHR domain of gp41 [12,13,49]. These observations led to a
broad belief that T20 inhibits HIV-1 fusion and entry by blocking viralTable 3
Combination index and dose reduction values for inhibition of HIV-1-mediated cell-cell fus
% Inhibition CI T20
Concentration (nM) D
Alone Mixed
Inhibition of HIV-1-mediated cell-cell fusion
50 0.004 10.490 0.023
75 0.004 13.806 0.029
90 0.003 18.171 0.038
95 0.003 21.905 0.045
Inhibition of HIV-1 IIIB infection
50 0.040 19.799 0.324
75 0.040 26.830 0.427
90 0.039 36.368 0.564
95 0.039 44.735 0.682
a Data are representative of two separate experiments. Each sample was tested in triplica
tions is 8:1 (in molecular concentration).gp41 6-HB core formation, much like C34 which is derived from the
N-terminal region of the gp41 CHR domain and partially overlaps the
sequence of T20.ion and HIV-1 IIIB infection by combinations of T20 and C34a.
C34
ose reduction Concentration (nM) Dose reduction
Alone Mixed
456.09 2.074 0.003 691.33
476.07 2.614 0.004 653.50
478.18 3.295 0.005 659.00
486.78 3.856 0.006 642.67
61.11 1.465 0.041 35.73
62.83 1.920 0.053 36.23
64.48 2.518 0.071 35.46
65.59 3.028 0.085 35.62
te, and the mean values are presented. Ratio of the peptides T20 and C34 in combina-
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have shown that T20, which lacks the PBD, cannot bind to the hydro-
phobic pocket region in the C-terminal region of the gp41 CHR do-
main, the critical site for 6-HB stability, and, thus, is not effective in
blocking viral gp41 fusion core formation [21,22]. Since T20 contains
the membrane- and N-NHR-binding domains, it may interact with
the lipid membrane of the target cell and the N-terminal region of
gp41 NHR domain, which contains a GIV motif, a determinant for
T20 resistance. This explains why the viruses with mutations in GIV
motif are highly resistant to T20, but only moderately resistant to
C34 [37]. Based on these ﬁndings, we have proposed that T20 inhibits
HIV-1 fusion by binding to the N-terminal region of the gp41 NHR
domain and the lipid membrane of the target cell, while C34 arrests
viral entry by interacting with the C-terminal region of the gp41
NHR domain and blocking viral gp41 6-HB formation. This hypothesis
is supported by an abundance of evidence from biophysical and
immunological studies [20–22,32,33], but it is not supported bymuta-
tion analysis since PBD-containing CHR peptides, such as T2635 and
sifuvirtide, could not induce drug-resistance mutations in the gp41
pocket region, but rather at sites far away from the pocket of gp41,
or even in some regions of gp120 [50–52]. It is possible that the resi-
dues in the pocket region, especially those located at the hydro-
phobic interface, are too conserved to mutate. Such peptides may
induce the mutations of residues outside the gp41 pocket to alter the
kinetics of 6-HB formation, thus limiting the time window for these
PBD-containing peptides can interfere with membrane fusion [53].
In our previous study, we substituted the residue Gln, a polar res-
idue, at position 64 in the pocket region at the c site in the NHR helical
wheel with Ala, a smaller amino acid with no polarity (Q64A), or Leu,
a hydrophobic residue (Q64L). We found that these mutants retained
substantial infectivity, but were highly resistant to CP32M, a PBD-
containing CHR peptide [37]. In this study, we used a similar approach
to study the resistance mechanism of C34 by selecting residue A67 at
the f site in the NHR helical wheel for mutations (Figs. 1B and C). We
found that viruses with pseudoviruses having A67G mutation in gp41
exhibited high infectivity, while those with A67D and A67S mutations
still maintained substantial infectivity (Fig. 2). These three mutants
were all highly resistant to C34, but they were relatively sensitive to
T20 (Fig. 3 and Table 1). In addition, these mutations had negative
effect onα-helical conformation, stability and other biophysical prop-
erties of the gp41 6-HB (Figs. 4 and 5). The NHR-peptides with muta-
tions of A67 exhibited decreased α-helicity (Fig. 4A) and reduced
anti-HIV-1 activity (Fig. 6). All these changes might contribute to
the resistance of A67 mutants to C34.
Since A67 is not located at the hydrophobic interface, change of
this residue may not signiﬁcantly affect the direct interaction be-
tween the NHR and CHR. However, this residue may play a role in
maintaining the appropriate conformation of the NHR-trimer core
formation. Changes of size (A→G) or polarity (A→S) of A67 could af-
fect the conformation of the hydrophobic pocket in the groove of the
NHR-trimer, resulting in improper binding of PBD-containing pep-
tides, like C34, and resistance of the viral mutants to C34. These re-
sults clearly demonstrated that C34 and T20 target different sites in
the gp41 NHR, thus reﬂecting different mechanisms of action in
inhibiting HIV-1 fusion and entry.
Combinatorial use of antiretroviral drugs with different targets or
mechanisms of action, such as the highly active antiretroviral therapy
(HAART), could signiﬁcantly increase antiviral potency based on syn-
ergism and delay of emerging drug resistance [54]. We previously
showed that the combinatorial use of T20 with a PBD-containing
CHR peptide, such as T1144 or sifuvirtide, resulted in strong synergis-
tic anti-HIV-1 effect [42,55]. Here, we showed, for the ﬁrst time, that
the combination of T20 with C34 also displayed highly potent syner-
gistic antiviral effect against HIV-1 Env-mediated cell-cell fusion and
HIV-1 IIIB infection (Table 3), conﬁrming that T20 and C34 have differ-
ent target sites of action. Interestingly, the combination of T20 and C34also exhibited strong synergistic antiviral effect against both T20- and
C34-resistant HIV-1 strains (Fig. 7), suggesting a potential regimen for
treatment of HIV/AIDS patients who fail to respond to T20 and other
HIV entry inhibitors.
In conclusion, using a single-point mutation strategy, we have
demonstrated that T20, a CHR-peptide containing MBD and N-NHR-
binding domain but lacking PBD, and C34, a PBD-containing CHR-
peptide, inhibit HIV-1 fusion by interacting with different target
sites. Combining T20 and C34 exhibits strong synergistic antiviral ac-
tivity against HIV-1 strains, including those resistant to T20 and C34.
Therefore, this study provides a theoretical basis for the rational de-
sign of novel HIV-1 entry inhibitors and/or more effective regimens
for treating patients infected with HIV-1 strains resistant to different
HIV entry inhibitors.
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